chrisvoncsefalvay/vaers-outcomes huggingface dataset:
4/23/18 - patient felt "beat up" after getting the vaccine. 4/23/18 - Injection site is sore, red, and warm.
I had my vaccination on 09/30/2022. On 03/23/2023 I woke up feeling dizzy and lethargic. I felt like I was getting chills and a head cold. I did a test COVID-19 and it was Positive on 03/23/2023. I went to the emergency room as I had tightness on my chest. I was prescribed Paxlovid. I presently feel better but I am still fatigued on 04/03/2023.
My bloodwork for a my annual exam -showed an elevated PSA - May 2021; they did an MRI and found lesions. Then they did biopsy and they discovered cancer - Prostrate - August 3rd, I think. Verified it was cancer on the August 19th. Urologist - He's the one that is going to do the operation. The operations is scheduled for the 21st of September - they will remove my prostrate. Not experiencing any symptoms.
6 days after 1st dose, pt developed a hematoma at site of subcutaneous injection.  Saw PCP and had ultrasound done diagnosing it as a hematoma.  Resolved before 2nd dose.  No treatment given.  1 day after 2nd dose, pt developed blisters at site of intradermal injection, red (>10 cm), swelling and itching.  Saw PCP.  Treating with calamine lotion.
Delayed period by 10 days. My cycle comes like clock work every month. Also had different PMS including cramping and excess bloating. No change in lifestyle or diet.
FATIGUE; This spontaneous report received from a vaccine facility via a company representative concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown, expiry: UNKNOWN) dose was not reported, administered on MAR-2021 for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported.  On MAR-2021, the subject experienced fatigue. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from fatigue on MAR-2021. This report was non-serious.
PRE-SYNCOPE; 3 NOSE BLEEDS; HIGH BLOOD PRESSURE; This spontaneous report received from a patient concerned a female of unspecified age. The patient's height, and weight were not reported. The patient's pre-existing medical conditions included the patient was not pregnant at the time of reporting. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 13-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On 2021, the subject experienced pre-syncope. On 2021, the subject experienced 3 nose bleeds. On 2021, the subject experienced high blood pressure. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from pre-syncope, and the outcome of 3 nose bleeds and high blood pressure was not reported. This report was non-serious.; Sender's Comments: V0 : Medical assessment comment not required as per standard procedure as the case was assessed as non-serious.
Adverse event presenting to pharmacist as Severe Hives/itching starting day 10 post booster vaccine. Hives are intermittent/continuous 24 hours a day and have lasted since day 10, now on day 4.
pt recv vax 29JUL94 & MAY95 pt exp 2-3 sz like sx;pharmacist not certain whether sx were related to vax;pt to be eval by neurologist on 15MAY95;
I got the Covid Vaccine and Wondering I have been having increasingly shortness of breath for last few days; gotten worse everyday its a little bit worse; This is a spontaneous report from a contactable nurse. This nurse reported for self that the 37-year-old female patient received first dose of bnt162b2 (BNT162B2, lot: EJ1685, Expiration Date: Mar2021), via Intramuscular on left deltoid on 20Dec2020 at single dose for covid-19 immunisation. Medical history was none. Concomitant medications included Multivitamins  and escitalopram oxalate (LEXAPRO). Nurse stated, "I was wondering I got the Pfizer (Covid) Vaccine on 20th and I have been having increasingly shortness of breath for last few days and I am wondering if that's the typical side effect of that. It wasn't prescribed, it was something given out to all the healthcare providers. It was like the first dose. It was first dose. I got an Intramuscular shot in left shoulder. Because I wanted to not spread it (Covid). I am not sure if it is due to the product, I got "6" (not clarified) from another patient, that's why I am calling, I want to know if this is like the typical side effect of vaccination or should I go get tested. I haven't taken any treatment yet. It's gotten worse everyday its a little bit worse." The outcome of the events was not recovered.
Per mom patient broke out in five pruritic bumps with red skin in chest, back and legs, + swelling around eyes, + wheezing resolved with BENADRYL and albuterol.
Shot administered 10/05/2009 reactions - night of 10/05 severe pounding headache. 10/06/09 skin rash on back - red itchy whelps spread across back, arms, shoulders, areas felt hot & terribly itchy!!! Still recovering.
Later that night, vaccination area was hurting and red. The next day vaccine area hot and getting a fever. By night fever was 101; took 2 TYLENOLS. On Saturday, fever continued went to ER. At ER, examined by NP first then doctor marked the vaccination spot (3x5) to see if it extended. Given KEFLEX (500mg 3 x day) for possible cellulitis. Fever went down and spot never grew bigger. Two days later the symptoms (pain/heat) at vaccination site resolved. Patient will complete antibiotic dose although symptoms have resolved already. Patient did not contact doctor yet. Patient reports no problems after first dose of SHINGRIX vaccine.
This spontaneous report was received from a healthcare worker (medical assistant) and refers to an unspecified number of patients of unknown age and gender. No information regarding the patients' medical history, concurrent conditions and concomitant therapies was provided. On unknown dates since 29-OCT-2015, the patient were vaccinated with improperly stored doses of RECOMBIVAX HB (lot # K012875, expiration date 27-AUG-2016, exact doses and route of administration were not reported). It was reported that since 29-OCT-2015, the vaccines were exposed to temperature of 32.3F during cumulative of 7 hours. No adverse effects were reported. No PQC (product quality complaint) was involved. This is one of several reports received form the same source. Additional information has been requested.
Tired for 1day; full body soreness 1 day; This is a spontaneous report received from Pfizer Program via a non-contactable consumer (patient). A patient of unspecified age and gender received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date as single dose for covid-19 immunisation. The patient medical history and concomitant medications were not reported.  The patient experienced tired for 1 day, and full body soreness 1 day. The outcomes of events were unknown.     No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Lg. (about 4 cm) area of induration at vaccine site with a few spots. And, about 20 other maculopapular lesions on extremities that are pruritic.
This spontaneous report as received from a registered nurse refers to a male patient of unknown age. The patient's medical history and concurrent conditions were not reported. On 11-AUG-2015, the patient was vaccinated with a dose of ROTATEQ, oral (dose, lot number and expiration date were not reported). No co-suspect and concomitant therapies were reported. The reporter stated that the patient immediately vomited once after receiving the dose of ROTATEQ (on 11-AUG-2015). The nurse reported that the patient fully recovered after vomiting once. The causality was not reported. Additional information has been requested.
Initial report received from a patient's parent, who is a nurse practitioner, on 12 September 2008. A 14-year-old male patient developed lethargy, fatigue, chills, loose stools and nausea 10 days after he had received an intramuscular left deltoid injection of Menactra (lot number not known). The patient also experienced dizziness approximately one week after the vaccination. Lethargy, chills and loose stools resolved in 72 hours. The dizziness also resolved at an unspecified time. At the time of the report, nausea and fatigue continued. Follow-up informaton was received 08 october 2008 from a health care professonial who reviewed the casre information and stated that the patient had a concomitant diagnosis of mononucleosis and had recovered from the event. No further information was provided at the time of the report.
NO ENERGY; FEEL BAD; EXTREME FATIGUE/SO TIRED; This spontaneous report received from a patient concerned a 63 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included: uterine cancer, anemia, and diabetic. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1808978, expiry: 11-SEP-2021) dose was not reported, administered on 23-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On 23-MAR-2021, the patient experienced extreme fatigue/so tired. On an unspecified date, the patient experienced no energy, and feel bad. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from extreme fatigue/so tired on 23-MAY-2021, and no energy, and the outcome of feel bad was not reported. This report was non-serious.
Large red blotch days 2-3 post vaccine.  Went away, then returned with large red raised splotch 1 week post-vaccine that changed and grew days 7-10 taking up much of the upper arm.   Appears to be gone now 2 weeks post-vaccine.
Headache; Nausea; Soreness; Exhaustion; Chills; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 22 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm right, administration date 05Mar2021 12:00 (Lot number: EN6202) at the age of 22 years as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: HEADACHE (non-serious) with onset 05Mar2021 12:45, outcome "recovered" (Mar2021), described as "Headache"; NAUSEA (non-serious) with onset 05Mar2021 12:45, outcome "recovered" (Mar2021), described as "Nausea"; PAIN (non-serious) with onset 05Mar2021 12:45, outcome "recovered" (Mar2021), described as "Soreness"; FATIGUE (non-serious) with onset 05Mar2021 12:45, outcome "recovered" (Mar2021), described as "Exhaustion"; CHILLS (non-serious) with onset 05Mar2021 12:45, outcome "recovered" (Mar2021), described as "Chills". Therapeutic measures were not taken as a result of headache, nausea, pain, fatigue, chills. Additional information: Facility type vaccine where patient received vaccine reported as Pharmacy or Drug Store. No other vaccine in four weeks. No other medications in two weeks. No COVID prior vaccination. No COVID tested post vaccination. No known allergies reported.   No follow-up attempts are possible. No further information is expected.
Information has been received from a registered nurse regarding a patient of an unknown age and gender. On 14-DEC-2012 at 07:45, ZOSTAVAX lot # H016765 was exposed to -14C for an estimated total time out of range of 13.25 hours. On 18-DEC-2012 at 18:30, ZOSTAVAX lot # H016765 was exposed to -14C for an estimated total time out of range of 12.75 hours. On 22-DEC-2012 at 18:30, ZOSTAVAX lot # H016765 was exposed to -14C for an estimated total time out of range of 5 hours. On 17-JAN-2013 at 07:45, ZOSTAVAX lot # H016765 was exposed to -14C for an estimated total time out of range of 14.25 hours. On 30-JAN-2013 at 18:00, ZOSTAVAX lot # H016765 was exposed to -14C for an estimated total time out of range of 10.5 hours. On 01-FEB-2013, the patient was vaccinated with an out of range dose of ZOSTAVAX (dose and route administration were not provided) (Lot number H016765). No adverse experience had been reported. This is one of 182 reports from the same source. Additional information has been requested.
A report has been received from a health professional concerning a 17 year old. female subject, who had been receiving nasal FLUMIST Quadrivalent.  FLUMIST Quadrivalent started on an unknown date. Reporter stated that none of the six patients presented any adverse reaction after receiving expired FLUMIST Quadrivalent. The outcome of the event of administration of expired product is unknown. The report was considered to be non-serious.
Increased asthma attacks; Severe runny nose; This spontaneous case was reported by a physician and describes the occurrence of RHINORRHOEA (Severe runny nose) and ASTHMA (Increased asthma attacks) in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 053E21A, 031M20A and 011J20A) for COVID-19 vaccination.     Concurrent medical conditions included Autoimmune disorder, Asthma and Drug allergy (Gabapentin makes her nauseated and have vertigo). Concomitant products included FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE (ADVAIR) for an unknown indication.   On 07-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 27-Aug-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 28-Aug-2021, the patient experienced RHINORRHOEA (Severe runny nose). On an unknown date, the patient experienced ASTHMA (Increased asthma attacks). The patient was treated with LEVALBUTEROL [LEVOSALBUTAMOL] for Adverse event, at a dose of unk, Nebulizer; ITRACONAZOLE (ITRACONAZOLE EG) for Sinus infection, at an unspecified dose and frequency and AZITHROMYCIN (ZITHROMAX) for Adverse event, at an unspecified dose and frequency. At the time of the report, RHINORRHOEA (Severe runny nose) and ASTHMA (Increased asthma attacks) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient thought that might had react more to the vaccine this time around, felt like faucet, patient  was checking a box of Kleenex everyday. Other treatment medication included antihistamines.   This case was linked to MOD-2021-323634, MOD-2021-323615 (Patient Link).
chills; 97 Fever; aches and pains; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 77 year-old patient received bnt162b2 (BNT162B2), administered in arm left, administration date 13Mar2021 10:00 (Lot number: EN6198) as dose 2, single for covid-19 immunisation; influenza vaccine (FLU), administration date 12Sep2021 (Batch/Lot number: unknown) as dose 1, single. Relevant medical history included: "Osteoporosis", start date: 2001 (ongoing); "Arthritis" (ongoing); "High cholesterol" (ongoing); "Hypothyroidism" (ongoing). Concomitant medication(s) included: SIMVASTATIN taken for blood cholesterol increased, start date: 2005 (ongoing); LEVOTHYROXIN taken for hypothyroidism, start date: 2005 (ongoing); VITAMIN D2, start date: Jun2021 (ongoing). Vaccination history included: Bnt162b2 (1st dose, Time: 11 , Anatomical site of injection; Left arm, Batch/Lot no: EN9200), administration date: 20Feb2021, for Covid-19 immunization. The following information was reported: PYREXIA (non-serious) with onset 13Sep2021 12:30, outcome "recovered" (14Sep2021), described as "97 Fever"; PAIN (non-serious) with onset 13Sep2021 11:30, outcome "recovered" (14Sep2021), described as "aches and pains"; CHILLS (non-serious) with onset 13Sep2021 13:00, outcome "recovered" (2021), described as "chills". The patient underwent the following laboratory tests and procedures: body temperature: (13Sep2021) 97. Therapeutic measures were taken as a result of pyrexia, pain. Therapeutic measures were not taken as a result of chills.   Additional information: The patient received Tylenol medication for the event pyrexia and pain .    No follow-up attempts are possible. No further information is expected.
numbness to lips day after vaccine tingling and numbness to left arm, progressively getting worse no drooping to face hives injection site pain
PFIZER COVID VACCINE #3 GIVEN 11/9/21, LOT #FE3590; 3/9/22 pt brought to ED via EMS for dyspnea, cough, weakness; saw PCP (Dr.) 3/8/22 with same sx; XRAYS done showing effusion right lobe; no other tx; O2 saturation 84% in ED on RA; positive for COVID; respiratory status worsened requiring intubation;  became unresponsive and no pulse at one point, CPR given, code called; grave condition; pt appears to have GI bleed after NG Tube placed; septic; COVID pneumonia; given IV fluids, ABX, blood; transitioned to comfort measures only; extubated and pt passed away in the hospital
Extreme pain in stomach, unable to take deep breath, accute pain continued for 4 hours; less painful for 5 days. Went to Urgent care  on 3rd day.
The patient had received a Janssen in January 2022 as his first COVID vaccine dose.  He presented today for a booster and was administered a monovalent Pfizer (gray cap) instead of the bivalent Pizer.   I am reporting a vaccine error- none an adverse event at this time.
nausea, no vomiting. feeling flush, shakey, and anxious. No SOB, pruritis.   Moved to a quiet room. Lay down for 45 minutes and observed. symptoms spontaneously subsided.
suspected Vaccination failure; shingles blister; Shingles blister; tingling down his left leg; This case was reported by a consumer via call center representative and described the occurrence of suspected vaccination failure in a 63-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included shingles (had a history of shingles since the age of 50 years).   On 13th October 2020, the patient received the 2nd dose of Shingrix. On 11th August 2020, the patient received the 1st dose of Shingrix. On 23rd November 2020, 41 days after receiving Shingrix and 104 days after receiving Shingrix, the patient experienced vaccination failure (serious criteria GSK medically significant), shingles, blister and tingling of extremity. On an unknown date, the outcome of the vaccination failure, shingles, blister and tingling of extremity were unknown.   It was unknown if the reporter considered the vaccination failure, shingles, blister and tingling of extremity to be related to Shingrix and Shingrix.  Additional details were provided as follows: The patient stated he started to feel the tingling down his left leg and had a shingles blister, the size of a quarter on his left buttock. This case was considered to be a suspected vaccination failure case, as the details laboratory confirmation for shingles was unknown. Consented to follow up.
Patient got nauseous and clammy post vaccination. He was nervous and worked up prior to.  We put his feet up and gave him some water. He felt better in 15 minutes and went back to work.
Gradual onset of feeling like I was going to fall while walking.  No dizziness, headache, or vomiting.  No vision problems either.  Went to PMD and had MRI done with no abnormal findings. Sent to special testing location. Found to possibly have an issue with inflammation or delays in pathways of the nerves from the inner ear to the brain. Not vertigo.  Currently doing PT to hopefully remedy this.
Patient received a 3rd dose of Covid19 (Moderna) due to the  nursing home facility representative bringing incorrect patient for immunization. The intended patient was for a 2nd dose, however the nursing home mistakenly identified the wrong patient as the intended recipient. The incorrect patient had already completed the covid19 2 dose series (1/6/21 and 2/3/21). Patient was observed for an extended time, No adverse events noted during the extended observation. Nursing home instructed to continue to observe patient over the next 48-72 hours and informed that patient may exhibit stronger side effects as a result of receiving a 3rd dose.  Additionally, facility instructed that there are  currently no documented recommendations from them for this administration error.
Jan 2022: Headaches and pressure behind eyes March 2022: Inner vibrations and head tremor (head twitches), pulsating sensations, red eyes,  July 2022: (First infection with Covid 19, positive for 12 days), intensified tremors and vibrations, onset of neuropathy in hands and feet Oct 2022: (Exposure to Covid 19), Neuropathy spread to legs and arms, racing heart, palpitations and pounding heart, fatigue, Nov 2022: Symptoms above intensified, neuropathy started in face, intolerance to sound and light started, headaches (had to give up my job), wasn't able to look into screens or socialize anymore. Best place was a dark and quiet room.  Dec 2022: Neuropathy was getting intenser in my face, nose, ears and cheeks
I got hives, they first started on my arms. They traveled around, I had to wait to see a doctor and they prescribed Percocet, PEPCID 20 mgs twice a day, to help with the hives. They changed locations, one day it could be my legs or arms and then my back. They appear and disappear, I'm currently still dealing with the hives.
This is in follow-up to report(s) previously submitted on 2/13/2009. Information has been received from a nurse practitioner concerning a 20 year old female with no known drug reaction/allergies and a history of exercise induced asthma who on 02-JUL-2008 was vaccinated with the first dose of GARDASIL vaccine, 0.5ml, intramuscularly. On 05-AUG-2008 was vaccinated with the second dose of GARDASIL vaccine, 0.5ml, intramuscularly and on 12-JAN-2009 was vaccinated with the third dose of GARDASIL vaccine 0.5ml, intramuscularly. The nurse practitioner reported that on 12-JAN-2009, the patient experienced bruising after receiving her third dose of GARDASIL. The nurse also reported that the patient received the third dose as an intramuscular injection that was administered below the deltoid region of the arm. The lot numbers for the vaccines were not available. The patient recovered on an unspecified date. The patient sought medical attention calling to nurse's practice. In follow-up the nurse practitioner reported that she was a 20 year old female patient weighing 131 pounds and 65 7/6 in height, with no known drug reaction/allergies and no medical conditions (previously reported as with history of exercise induced asthma), who on 02-JUL-2008 was vaccinated with the first dose of GARDASIL (Lot # 660555/0279X) intramuscularly: on 05-AUG-2008 was vaccinated with the second dose of GARDASIL (660557/0072X), intramuscularly and on 12-JAN-2009 was vaccinated with the third dose of GARDASIL (Lot #663531/1311X), intramuscularly in the arm. There were no illnesses at the time of vaccination. The nurse practitioner reported that the patient's mother stated that vaccine was administered too low, just below deltoid muscle and there was a bruising associated with the injection. The mother was concerned that improper placement may impair absorption and diminish vaccine efficacy. The patient recovered on 14-JAN-2009. No further information is available.